All In Biotech

Drug Trial Radar · NCT02013154

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies

Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

151

Actual

Start

May 5, 2014

Primary completion

Jul 19, 2019

Study completion Jan 11, 2021

Sponsor

Lead sponsor
Leap Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Dec 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies

Conditions

  • Esophageal Neoplasms
  • Adenocarcinoma of the Gastroesophageal Junction
  • Gastroesophageal Cancer
  • Squamous Cell Carcinoma
  • Gastric Adenocarcinoma

Interventions

  • DKN-01 150 mgDrug

    Administered by IV infusion

  • PaclitaxelDrug

    Administered by IV infusion

  • PembrolizumabDrug

    Administered by IV infusion

  • DKN-01 300 mgDrug

    Administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with dose limiting toxicities in each treatment armTime frame: Baseline to End of Cycle 1 (each cycle is 28 days, except each cycle is 21 days when DKN-01 is administered with pembrolizumab)
  2. Number of subjects with treatment emergent adverse events related to study treatment (DKN-01 as monotherapy or in combination with paclitaxel or pembrolizumab)Time frame: Baseline until 30 days after last dose of study drug

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Care Foundation

    Los Angeles, California

  • Smilow Cancer Hospital at Yale - New Haven

    New Haven, Connecticut

  • Northwestern University

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Duke University

    Durham, North Carolina

  • Tennessee Oncology / Sarah Cannon Research Institute

    Nashville, Tennessee

  • Vanderbilt University / VICC

    Nashville, Tennessee

  • Mary Crowley Cancer Center

    Dallas, Texas

  • CTRC @ The University of Texas Health Science Center at San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.